Imaging in Dementia:
|
|
- Edward Fields
- 6 years ago
- Views:
Transcription
1 Imaging in Dementia: Options for Clinical Practice 2017 John A. Bertelson, MD Clinical Chief of Neurology, Seton Brain and Spine Institute Assistant Professor of Medicine, Dell Medical School, UT Austin Clinical Assistant Professor of Psychology, UT Austin
2 None Disclosures
3 Outline Early Imaging Indications for Imaging in Dementia Imaging of Alzheimer s Disease Imaging of Other Dementing Disorders Future Directions
4 Early Dementia Imaging- Pneumoencephalography Initially described in Low resolution High morbidity, including: Meningeal irritation, 6 hrs: Headache Nausea Emesis Elevation in BP Became obsolete in : AJNR :
5 Modern Imaging
6 Traditional Role for Neuroimaging in Dementia Indication: Rule out reversible process Quality Standards Subcommittee of the AAN, 1994: Neuroimaging should be considered in every patient with dementia potentially treatable disorders that can otherwise be missed, such as tumors, subdural hematomas, hydrocephalus, and strokes. there is no consensus on the need for such studies in the evaluation of patients with the insidious onset of dementia after age 60 without focal signs or symptoms, seizures, or gait disturbances. Alter M, 1994
7 Evolution of Indications for Neuroimaging in Dementia Entity Year Recommendations AAN 1994 Neuroimaging is not routinely recommended CCCD 1999 Neuroimaging (head CT) is recommended only in select situations AAN 2001 Structural neuroimaging (noncontrast CT or MRI) is appropriate in the routine initial evaluation of patients with dementia Structural imaging is recommended in every patient suspected of dementia: EFNS Noncontrast CT can identify surgically treatable lesions and vascular disease. - To increase specificity, MRI should be used. EFNS 2012 Structural imaging (CT or MRI) is recommended in the routine evaluation of every patient with dementia, to exclude secondary causes of dementia. Key: AAN: American Academy of Neurology CCD: Canadian Consensus Conference on Dementia EFNS: European Federation of Neurological Subspecialties From: Bertelson and Ajtai, 2014
8 Reversible Causes of Dementia Copenhagen Memory Clinic Potentially reversible etiologies for cognitive symptoms In 1000 memory clinic patients 4-5% Hejl A 2002
9 Neuroimaging in Dementia
10 Alzheimer s Disease (AD)
11 Alzheimer s Disease The most common cause of dementia Affects over 5 million Americans 6th leading cause of death for people in the US Affects 1 in 9 age 65 and older, 1 in 3 over age 85 About 10% of people have early onset which affects people under age 65
12 Histopathologic Hallmarks of AD Major histopathologic hallmarks include Amyloid-β plaques Neurofibrillary tangles Neuronal and synaptic loss AP NFT AP = amyloid plaques. NFT = neurofibrillary tangles. Courtesy of Albert Enz, PhD, Novartis Pharmaceuticals Corporation.
13 Model of the Dynamic Biomarkers of Alzheimer s Disease Sperling RA, 2011
14 NIA-AA Diagnostic Criteria for Dementia due to Alzheimer s Disease Probable AD dementia w/ evidence of the AD pathophysiological process Possible AD dementia w/ evidence of the AD pathophysiological process Pathophysiologically proved AD dementia Biomarker Biomarker To improve the certainty that the basis of the clinical dementia syndrome is the AD pathophysiological process Dementia unlikely to be due to AD McKhann GM, 2011
15 AD Imaging Biomarkers Brain Aß amyloidosis PIB/florbetapir-PET Neuronal injury FDG-PET Brain Tau Deposition Tau tracer-pet MRI atrophy Medial temporal lobes Paralimbic Temporoparietal cortex
16 MRI and AD
17 Posterior Cortical Atrophy (PCA) Variant of AD Visuospatial impairment Prominent atrophy of parietal and occipital cortex
18 Automated volumetric MRI analysis Hippocampal Volume Eval. NeuroQuant, CorTechs Labs Inferior Lateral Vent. Commercially available Reported: Volumes of hippocampi (HV) and inferior lateral ventricle (ILV) Hippocampus Volumes as % of intracranial volume Normative %, based on age and gender
19 Volumetric MRI Analysis- NeuroQuant
20 Volumetric MRI Analysis- NeuroQuant
21 PET and AD FDG PET Amyloid PET Tau PET
22 FDG PET Medicare Guidelines in Dementia Effective 9/15/2004, An FDG PET scan is considered reasonable and necessary in patients with: a recent diagnosis of dementia, documented cognitive decline of at least 6 months, meet diagnostic criteria for both AD and FTD.
23 FDG PET Medicare Guidelines in Dementia Additional prerequisites include: Comprehensive evaluation already completed, including brain CT or MRI Evaluation by a physician experienced in the diagnosis and assessment of dementia Evaluation is indeterminate and FDG PET is reasonably expected to clarify the diagnosis between FTD and AD SPECT or PET have not already been obtained in the past 12 months AND significant clinical changes have occurred
24 FDG PET AD FTD PPA
25 Amyloid PET Imaging Pittsburgh Compound-B PET Pittsburgh Compound-B (PIB) Radiolabeled thioflavin derivative T1W-MRI PIB- PET [N-methyl-(11)C]2-(4 - methylaminophenyl)-6- hydroxybenzothiazole Control Selectively binds to amyloid plaque and cerebrovascular amyloid Significant retention seen in: 90+% AD patients 60% patients with MCI 30% normal elderly AD Very short half life: 20 minutes Mathis J Med Chem 2003;46(13) Applied Neurology, Nov (suppl) Mosconi J Alzheimer s Dis 2010
26 Amyloid-binding Radionucleotides Florbetapir (Amyvid) 1 Marketed in US by Eli Lilly Approved by FDA, not covered by CMS for routine use 2 Half life 110 minutes Additional FDA-approved radionucleotides 3 Florbetaben (Neuraceq, Piramal Imaging) Flutemetamol (Vizamyl, GE Healthcare) 1: Florbetapir, package insert 2: CMS Memo (CAG-00431N) 3: Alzforum, downloaded
27 Tau vs. Aβ Imaging
28 Tau vs Aẞ Imaging in Alzheimer s Disease Human postmortem studies have shown that it is the density of NFTs and not of Aẞ insoluble plaques that strongly correlates with neurodegeneration and cognitive deficits 1 PET imaging studies suggest that tau deposition more closely correlates with cognition than Aẞ deposition 2 1. Villemagne Brier et al. 2016
29 Tau in the Brain Phosphoprotein 6 isoforms Stabilizes microtubules Cytoskeletal support Intracellular transport (organelles, neurotransmitters, etc) Associated with AD, PSP, CBGD, CTE, and several variants of FTD.
30 Tau PET Tracers Ideal tau PET tracer High affinity for phosphorolated tau and neurofibrillary tangles Weak affinity for tau monomers and amyloid 7+ tau tracers developed (F-18)T807 in phase 2 trials
31 Tau PET: (F-18) T807 A. Normal Axial Sagittal Coronal B. AD James 2015
32 Frontotemporal Degeneration (FTD)
33 Frontotemporal Dementia Subtypes Behavioral variant (bvftd) Language variant (Primary Progressive Aphasia, PPA) Nonfluent/agrammatic Semantic Logopenic Gorno-Tempini 2011
34 Radiologist Diagnosis of FTD with MRI Review of cases of fronto-temporal dementia with brain MRI General radiologists only considered Pick s disease or bvftd in 10% of cases Neuroradiologists considered these diagnoses in 60% of cases Suarez 2009
35 Imaging Findings in FTD MRI Early: Normal or focal frontal, insular, or temporal atrophy Late: Progressive focal atrophy (usually bilateral) or generalized atrophy FDG PET Early: Hypometabolism in the frontal or temporal regions Late: Generalized hypometabolism Amyloid PET All stages: No significant binding
36 Progressive Cognitive Decline T=0 years T=3 years T=8 years
37 Progressive Cognitive Decline T=0 years T=3 years T=8 years P R I M A R Y P R O G R E S S I V E A P H A S I A
38 Tau PET Imaging in FTD variant: 18 F-AV-1451 (Tau) PET A-C: 3 patients with MAPT mutation D: normal control Smith and Puschmann, 2016
39 Tau PET Imaging in FTD variant: Inverse Relationship between Tau and FDG PET FDG PET Tau PET Smith and Puschmann, 2016
40 Imaging of Other Dementing Disorders
41 Huntington s Disease From: Bertelson and Ajtai, 2014
42 Progressive Supranuclear Palsy Atrophic midbrain Normal midbrain Reduced AP midbrain diameter From: Bertelson and Ajtai, 2014
43 Multiple System Atrophy
44 Multiple System Atrophy From: Bertelson and Ajtai, 2014
45 Prion Diseases
46 scjd A DWI hyperintense caudate and putamen B and C DWI hyperintense cortical ribbon From: Bertelson and Ajtai, 2014
47 Variant Creutzfeldt-Jakob Disease (vcjd) Hockey stick sign DWI hyperintensity in the bilateral medial thalami and pulvinar From: Bertelson and Ajtai, 2014
48 What s next?? Wider utilization of neuroimaging biomarkers to: Clarify the diagnosis Alzheimer s Disease vs. Non-Alzheimer s Dementias Monitor response to disease modifying agents Limitations Cost Access to advanced imaging Inadequacy of response to disease modifying agents
49 Clinical, genetic, and pathological spectrum of misfolded proteins in neurodegenerative disease Villemagne 2015
50 Thank You
51 Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, et al. Towards defining the preclinical stages of Alzheimer s disease: recommendations from the National Institute on Aging and the Alzheimer s Association workgroup. Alzheimers Dement 2011;7: References Villemagne, VL et al. Tau imaging: early progress and future directions. Lancet Neurology 14 :1(2015) Villemagne VL and Okamura N. In vivo tau imaging: Obstacles and progress. Alzheimer s and Dementia 10(2014) S James OG et al. PET imaging of tau pathology in Alzheimer s tauopathies. Frontiers in Neurology 6(2015): 1-4.
52 References Alter, M et al (Quality Standards Subcommittee of the AAN). Practice parameter for diagnosis and evaluation of dementia. Neurology 1994; 44: Knopman DS et al. Practice Parameter: diagnosis of dementia (an evidence-based review). Neurology 2001; 56: Hejl A et al. Potentially reversible conditions in 1000 consecutive memory clinic patients. J Neuro Neurosurg Psychiatry 2002; 73(4): Jack CR Jr, Albert M, Knopman D, McKhann G, Sperling R, Carrillo M, et al. Introduction to the revised criteria for the diagnosis of Alzheimer s disease: National Institute on Aging and the Alzheimer s Association workgroup. Alzheimers Dement 2011;7:
53 Kalkonde YV et al. Difference between clinical subspecialties in the outpatient evaluation and treatment of dementia in an academic medical center. Dement Geriatr Cogn Disord 2010; 29: References McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH, et al. The diagnosis of dementia due to Alzheimer s disease: recommendations from the National Institute on Aging and the Alzheimer s Association workgroup. Alzheimers Dement 2011;7: Albert M, DeKosky ST, Dickson D, Dubois B, Feldman H, Fox NC, et al. The diagnosis of mild cognitive impairment due to Alzheimer s disease: report of the National Institute on Aging and the Alzheimer s Association workgroup. Alzheimers Dement 2011;7:270-9.
54 References Borghesani PR et al. Neuroimaging in the clinical diagnosis of dementia: observations from a memory disorders clinic. Journal of the American Geriatrics Society 2010; 58(8): Heister D et al. Predicting MCI outcome with clinically available MRI and CSF biomarkers. Neurology 2011; 77: Dickerson BC et al. Alzheimer-signature MRI biomarker predicts AD dementia in cognitively normal adults. Neurology 2011; 76: Dickerson BC et al. MRI cortical thickness biomarker predicts AD-like CSF and cognitive decline in normal adults. Neurology 2012; 78:
55 References Petersen RC. New clinical criteria for the Alzheimer s Disease Spectrum. Minnesota Medicine Price DL et al. Investigation of acoustic noise on 15 MRI scanners from 0.2T to 3T. J Magn Reson Imaging 2001; 13(2): Li TQ and Wahlund LO. The search for neuroimaging biomarkers of Alzheimer's disease with advanced MRI techniques. Acta Radiologica. 2011; Vol. 52 (2): Gorno-Tempini ML et al. Classification of primary progressive aphasia and its variants. Neurology 2011; 76: Snowden JS et al. Distinct behavioural profiles in frontotemporal dementia and semantic dementia. J Neurol Neurosurg Psychiatry 2001; 70:
56 References Rabinovici GD, Rosen HJ, etal. Amyloid vs. FDG-PET in the differential diagnosis of AD and FTLD. Neurology 2011; 77: Suárez J et al. Characterizing radiology reports in patients with frontotemporal dementia. Neurology 2009; 73(13): Kerholz K et al. Positron emission tomography imaging in dementia. British Journal of Radiology 2007; 80:S Mosconi L et al. Pre-clinical detection of Alzheimer s disease using FDG-PET with or without amyloid imaging. J Alzheimers Dis. 2010; 20(3): Laino C Two radioactive tracers detect amyloid, may aid in AD diagnosis. Neurology Today 2012; 12(10): 16-7.
DISCLOSURES. Objectives. THE EPIDEMIC of 21 st Century. Clinical Assessment of Cognition: New & Emerging Tools for Diagnosing Dementia NONE TO REPORT
Clinical Assessment of Cognition: New & Emerging Tools for Diagnosing Dementia DISCLOSURES NONE TO REPORT Freddi Segal Gidan, PA, PhD USC Keck School of Medicine Rancho/USC California Alzheimers Disease
More informationForm D1: Clinician Diagnosis
Initial Visit Packet Form D: Clinician Diagnosis NACC Uniform Data Set (UDS) ADC name: Subject ID: Form date: / / Visit #: Examiner s initials: INSTRUCTIONS: This form is to be completed by the clinician.
More informationNeuro degenerative PET image from FDG, amyloid to Tau
Neuro degenerative PET image from FDG, amyloid to Tau Kun Ju Lin ( ) MD, Ph.D Department of Nuclear Medicine and Molecular Imaging Center, Chang Gung Memorial Hospital ( ) Department of Medical Imaging
More informationFRONTOTEMPORAL DEGENERATION: OVERVIEW, TRENDS AND DEVELOPMENTS
FRONTOTEMPORAL DEGENERATION: OVERVIEW, TRENDS AND DEVELOPMENTS Norman L. Foster, M.D. Director, Center for Alzheimer s Care, Imaging and Research Chief, Division of Cognitive Neurology, Department of Neurology
More informationYin-Hui Siow MD, FRCPC Director of Nuclear Medicine Southlake Regional Health Centre
Yin-Hui Siow MD, FRCPC Director of Nuclear Medicine Southlake Regional Health Centre Today Introduction to CT Introduction to MRI Introduction to nuclear medicine Imaging the dementias The Brain ~ 1.5
More informationDementia: A Comprehensive Update Neuroimaging, CSF, and genetic biomarkers in dementia
Dementia: A Comprehensive Update 2016 Neuroimaging, CSF, and genetic biomarkers in dementia Bradford C. Dickerson, M.D. Associate Professor of Neurology, Harvard Medical School Departments of Neurology
More informationDiagnosis before NIA AA The impact of FDG PET in. Diagnosis after NIA AA Neuropathology and PET image 2015/10/16
The impact of FDG PET in degenerative dementia diagnosis Jung Lung, Hsu MD, Ph.D (Utrecht) Section of dementia and cognitive impairment Department of Neurology Chang Gung Memorial Hospital, Linkou, Taipei
More informationMoving Targets: An Update on Diagnosing Dementia in the Clinic
Moving Targets: An Update on Diagnosing Dementia in the Clinic Eric McDade DO Department of Neurology School of Medicine Alzheimer Disease Research Center Disclosures No relevant financial disclosures
More informationMild Cognitive Impairment (MCI)
October 19, 2018 Mild Cognitive Impairment (MCI) Yonas E. Geda, MD, MSc Professor of Neurology and Psychiatry Consultant, Departments of Psychiatry & Psychology, and Neurology Mayo Clinic College of Medicine
More informationImaging of Alzheimer s Disease: State of the Art
July 2015 Imaging of Alzheimer s Disease: State of the Art Neir Eshel, Harvard Medical School Year IV Outline Our patient Definition of dementia Alzheimer s disease Epidemiology Diagnosis Stages of progression
More informationComments to this discussion are invited on the Alzforum Webinar page. Who Should Use the New Diagnostic Guidelines? The Debate Continues
Comments to this discussion are invited on the Alzforum Webinar page. Who Should Use the New Diagnostic s? The Debate Continues Ever since new criteria came out for a research diagnosis of prodromal/preclinical
More informationIntroduction, use of imaging and current guidelines. John O Brien Professor of Old Age Psychiatry University of Cambridge
Introduction, use of imaging and current guidelines John O Brien Professor of Old Age Psychiatry University of Cambridge Why do we undertake brain imaging in AD and other dementias? Exclude other causes
More informationNew diagnostic criteria for Alzheimer s disease and mild cognitive impairment for the practical neurologist
New diagnostic criteria for Alzheimer s disease and mild cognitive impairment for the practical neurologist Andrew E Budson, 1,2 Paul R Solomon 2,3 1 Center for Translational Cognitive Neuroscience, VA
More informationProvider Led Entity. CDI Quality Institute PLE Neurocognitive Disorders AUC 02/05/2019
Provider Led Entity CDI Quality Institute PLE Neurocognitive Disorders AUC 02/05/2019 Appropriateness of advanced imaging procedures* in patients with a suspected neurocognitive disorder: *Including MRI,
More informationDementia Update. Daniel Drubach, M.D. Division of Behavioral Neurology Department of Neurology Mayo Clinic Rochester, Minnesota
Dementia Update Daniel Drubach, M.D. Division of Behavioral Neurology Department of Neurology Mayo Clinic Rochester, Minnesota Nothing to disclose Dementia Progressive deterioration in mental function
More informationDementia Update. October 1, 2013 Dylan Wint, M.D. Cleveland Clinic Lou Ruvo Center for Brain Health Las Vegas, Nevada
Dementia Update October 1, 2013 Dylan Wint, M.D. Cleveland Clinic Lou Ruvo Center for Brain Health Las Vegas, Nevada Outline New concepts in Alzheimer disease Biomarkers and in vivo diagnosis Future trends
More informationPerspectives on Frontotemporal Dementia and Primary Progressive Aphasia
Perspectives on Frontotemporal Dementia and Primary Progressive Aphasia Bradley F. Boeve, M.D. Division of Behavioral Neurology Department of Neurology Mayo Clinic Rochester, Minnesota Alzheimer s Disease
More informationStephen Salloway, M.D., M.S. Disclosure of Interest
Challenges in the Early Diagnosis of Alzheimer s Disease Stephen Salloway, MD, MS Professor of Neurology and Psychiatry Alpert Medical School, Brown University 2 nd Annual Early Alzheimer s Educational
More informationBrain imaging for the diagnosis of people with suspected dementia
Why do we undertake brain imaging in dementia? Brain imaging for the diagnosis of people with suspected dementia Not just because guidelines tell us to! Exclude other causes for dementia Help confirm diagnosis
More informationRound table: Moderator; Fereshteh Sedaghat, MD, PhD Brain Mapping in Dementias and Non-invasive Neurostimulation
Round table: Moderator; Fereshteh Sedaghat, MD, PhD Brain Mapping in Dementias and Non-invasive Neurostimulation 1. Reflection of Mild Cognitive Impairment (MCI) and Dementias by Molecular Imaging, PET
More informationUSE OF BIOMARKERS TO DISTINGUISH SUBTYPES OF DEMENTIA. SGEC Webinar Handouts 1/18/2013
Please visit our website for more information http://sgec.stanford.edu/ SGEC Webinar Handouts 1/18/2013 2013 WEBINAR SERIES STATE OF THE SCIENCE: DEMENTIA EVALUATION AND MANAGEMENT AMONG DIVERSE OLDER
More informationObjectives. Objectives continued: 3/24/2012. Copyright Do not distribute or replicate without permission 1
Frontotemporal Degeneration and Primary Progressive Aphasia Caregiver and Professional Education Conference Diana R. Kerwin, MD Assistant Professor of Medicine-Geriatrics Cognitive Neurology and Alzheimer
More informationHow can the new diagnostic criteria improve patient selection for DM therapy trials
How can the new diagnostic criteria improve patient selection for DM therapy trials Amsterdam, August 2015 Bruno Dubois Head of the Dementia Research Center (IMMA) Director of INSERM Research Unit (ICM)
More informationDementia. Stephen S. Flitman, MD Medical Director 21st Century Neurology
Dementia Stephen S. Flitman, MD Medical Director 21st Century Neurology www.neurozone.org Dementia is a syndrome Progressive memory loss, plus Progressive loss of one or more cognitive functions: Language
More informationMedicare Program; Reconciling National Coverage Determinations on Positron. Emission Tomography (PET) Neuroimaging for Dementia
This document is scheduled to be published in the Federal Register on 04/11/2018 and available online at https://federalregister.gov/d/2018-07410, and on FDsys.gov BILLING CODE 4120-01-P DEPARTMENT OF
More information#CHAIR2015. Miami, Florida. September 24 26, JW Marriott Miami. Sponsored by
#CHAIR2015 September 24 26, 2015 JW Marriott Miami Miami, Florida Sponsored by Case Challenge Workshop Alzheimer s Disease Anand Kumar, MD University of Illinois at Chicago, College of Medicine Chicago,
More informationreview of existing studies on ASL in dementia Marion Smits, MD PhD
review of existing studies on ASL in dementia Marion Smits, MD PhD Associate Professor of Neuroradiology Department of Radiology, Erasmus MC, Rotterdam (NL) Alzheimer Centre South-West Netherlands, Rotterdam
More informationRegulatory Challenges across Dementia Subtypes European View
Regulatory Challenges across Dementia Subtypes European View Population definition including Early disease at risk Endpoints in POC studies Endpoints in pivotal trials 1 Disclaimer No CoI The opinions
More informationMild Cognitive Impairment
Mild Cognitive Impairment Victor W. Henderson, MD, MS Departments of Health Research & Policy (Epidemiology) and of Neurology & Neurological Sciences Stanford University Director, Stanford Alzheimer s
More informationThe added value of the IWG-2 diagnostic criteria for Alzheimer s disease
The added value of the IWG-2 diagnostic criteria for Alzheimer s disease Miami, January 2016 Bruno Dubois Head of the Dementia Research Center (IMMA) Director of INSERM Research Unit (ICM) Salpêtrière
More informationDementia and Healthy Ageing : is the pathology any different?
Dementia and Healthy Ageing : is the pathology any different? Professor David Mann, Professor of Neuropathology, University of Manchester, Hope Hospital, Salford DEMENTIA Loss of connectivity within association
More informationNEXT-Link DEMENTIA. A network of Danish memory clinics YOUR CLINICAL RESEARCH PARTNER WITHIN ALZHEIMER S DISEASE AND OTHER DEMENTIA DISEASES.
NEXT-Link DEMENTIA A network of Danish memory clinics YOUR CLINICAL RESEARCH PARTNER WITHIN ALZHEIMER S DISEASE AND OTHER DEMENTIA DISEASES. NEXT-Link DEMENTIA NEXT-Link DEMENTIA is a network of Danish
More informationDementia Past, Present and Future
Dementia Past, Present and Future Morris Freedman MD, FRCPC Division of Neurology Baycrest and University of Toronto Rotman Research Institute, Baycrest CNSF 2015 Objectives By the end of this presentation,
More informationMultimodality Imaging of Alzheimer Disease and Other Neurodegenerative Dementias
CONTINUING EDUCATION Multimodality Imaging of Alzheimer Disease and Other Neurodegenerative Dementias Ilya M. Nasrallah and David A. Wolk Hospital of the University of Pennsylvania, University of Pennsylvania,
More informationNIH Public Access Author Manuscript Semin Neurol. Author manuscript; available in PMC 2014 November 14.
NIH Public Access Author Manuscript Published in final edited form as: Semin Neurol. 2013 September ; 33(4): 386 416. doi:10.1055/s-0033-1359312. Neuroimaging Biomarkers of Neurodegenerative Diseases and
More informationDEMENTIA 101: WHAT IS HAPPENING IN THE BRAIN? Philip L. Rambo, PhD
DEMENTIA 101: WHAT IS HAPPENING IN THE BRAIN? Philip L. Rambo, PhD OBJECTIVES Terminology/Dementia Basics Most Common Types Defining features Neuro-anatomical/pathological underpinnings Neuro-cognitive
More informationRole of TDP-43 in Non-Alzheimer s and Alzheimer s Neurodegenerative Diseases
Role of TDP-43 in Non-Alzheimer s and Alzheimer s Neurodegenerative Diseases Keith A. Josephs, MD, MST, MSc Professor of Neurology 13th Annual Mild Cognitive Impairment (MCI) Symposium: Alzheimer and Non-Alzheimer
More informationDisclosure Statement
Recommendations on MCI from the Third and Fourth Canadian Consensus Conferences on Diagnosis and Therapy of Dementia/ Quatrieme Conférence Canadienne Consensuelle sur la Démence 2012. Dr. Howard Chertkow
More informationChanging diagnostic criteria for AD - Impact on Clinical trials
Changing diagnostic criteria for AD - Impact on Clinical trials London, November 2014 Bruno Dubois Head of the Dementia Research Center (IMMA) Director of INSERM Research Unit (ICM) Salpêtrière Hospital
More informationTGF-ß1 pathway as a new pharmacological target for neuroprotection in AD. Filippo Caraci
Department of Clinical and Molecular Biomedicine Section of Pharmacology and Biochemistry Department of Educational Sciences University of Catania TGF-ß1 pathway as a new pharmacological target for neuroprotection
More informationTammie Benzinger, MD, PhD
Tammie Benzinger, MD, PhD benzingert@wustl.edu Disclosure: Tammie L.S. Benzinger, M.D., Ph.D. Research Support / Grants: NIH/NIA 5P01AG026276, 1U01AG032438, AG003991-27, 1R01NS066905-01, 1P01NS059560-01A1,
More informationSWI including phase and magnitude images
On-line Table: MRI imaging recommendation and summary of key features Sequence Pathologies Visible Key Features T1 volumetric high-resolution whole-brain reformatted in axial, coronal, and sagittal planes
More informationThe frontotemporal dementia spectrum what the general physician needs to know Dr Jonathan Rohrer
The frontotemporal dementia spectrum what the general physician needs to know Dr Jonathan Rohrer MRC Clinician Scientist Honorary Consultant Neurologist Dementia Research Centre, UCL Institute of Neurology
More informationClaims & Underwriting. You already told us that story! Maria C. Carrillo, Ph.D. Sr. Director, Medical & Scientific Relations Alzheimer s Association
Claims & Underwriting Alzheimer s & Cognitive Impairment: You already told us that story! Maria C. Carrillo, Ph.D. Sr. Director, Medical & Scientific Relations Alzheimer s Association 1 OVERVIEW Impact
More information8/14/2018. The Evolving Concept of Alzheimer s Disease. Epochs of AD Research. Diagnostic schemes have evolved with the research
The Evolving Concept of Alzheimer s Disease David S. Geldmacher, MD, FACP Warren Family Endowed Chair in Neurology Department of Neurology UAB School of Medicine Epochs of AD Research Epoch Years Key Event
More informationI do not have any disclosures
Alzheimer s Disease: Update on Research, Treatment & Care Clinicopathological Classifications of FTD and Related Disorders Keith A. Josephs, MST, MD, MS Associate Professor & Consultant of Neurology Mayo
More informationDiagnosis and Treatment of Alzhiemer s Disease
Diagnosis and Treatment of Alzhiemer s Disease Roy Yaari, MD, MAS Director, Memory Disorders Clinic, Banner Alzheimer s Institute 602-839-6900 Outline Introduction Alzheimer s disease (AD)Guidelines -revised
More information! slow, progressive, permanent loss of neurologic function.
UBC ! slow, progressive, permanent loss of neurologic function.! cause unknown.! sporadic, familial or inherited.! degeneration of specific brain region! clinical syndrome.! pathology: abnormal accumulation
More informationDifferential Diagnosis
Differential Diagnosis 2 2.1 Introduction AD accounts for up to 75 % of all dementia cases. The differential diagnosis with other conditions is sometimes challenging since several disorders may produce
More informationPart 2: Early detection, assessment and treatment in relation to the new guidelines. Christopher Patterson McMaster University
Part 2: Early detection, assessment and treatment in relation to the new guidelines Christopher Patterson McMaster University C. Patterson MD, FRCPC Division of Geriatric Medicine, McMaster University
More informationDiagnosing Dementia: Signs & symptoms, differential diagnosis of common dementias, and non-degenerative memory loss
Diagnosing Dementia: Signs & symptoms, differential diagnosis of common dementias, and non-degenerative memory loss Incidence of Common Neurological Diseases Incidence New Cases Disease (per 100,000) (per
More informationNeuropathology of Neurodegenerative Disorders Prof. Jillian Kril
Neurodegenerative disorders to be discussed Alzheimer s disease Lewy body diseases Frontotemporal dementia and other tauopathies Huntington s disease Motor Neuron Disease 2 Neuropathology of neurodegeneration
More informationOutline. Facts and figures Action plans Early / correct diagnosis Conclusions
Outline Facts and figures Action plans Early / correct diagnosis Conclusions Dementia: the greatest chalenge. Time to act now Philip Scheltens Professor of Neurology VU University Medical Center Amsterdam
More informationForm A3: Subject Family History
Initial Visit Packet NACC Uniform Data Set (UDS) Form A: Subject Family History ADC name: Subject ID: Form date: / / Visit #: Examiner s initials: INSTRUCTIONS: This form is to be completed by a clinician
More informationDiffusion Tensor Imaging in Dementia. Howard Rosen UCSF Department of Neurology Memory and Aging Center
Diffusion Tensor Imaging in Dementia Howard Rosen UCSF Department of Neurology Memory and Aging Center www.memory.ucsf.edu Overview Examples of DTI findings in Alzheimer s disease And other dementias Explore
More informationNeuroimaging Biomarkers of Neurodegenerative Diseases and Dementia
386 Neuroimaging Biomarkers of Neurodegenerative Diseases and Dementia Shannon L. Risacher, PhD 1 Andrew J. Saykin, PsyD 1 1 Center for Neuroimaging, Department of Radiology and Imaging Sciences, and Indiana
More informationConfronting the Clinical Challenges of Frontotemporal Dementia
Confronting the Clinical Challenges of Frontotemporal Dementia A look at FTD s symptoms, pathophysiology, subtypes, as well as the latest from imaging studies. By Zac Haughn, Senior Associate Editor Ask
More informationNeuroimaging for dementia diagnosis. Guidance from the London Dementia Clinical Network
Neuroimaging for dementia diagnosis Guidance from the London Dementia Clinical Network Authors Dr Stephen Orleans-Foli Consultant Psychiatrist, West London Mental Health NHS Trust Dr Jeremy Isaacs Consultant
More informationbrain MRI for neuropsychiatrists: what do you need to know
brain MRI for neuropsychiatrists: what do you need to know Christoforos Stoupis, MD, PhD Department of Radiology, Spital Maennedorf, Zurich & Inselspital, University of Bern, Switzerland c.stoupis@spitalmaennedorf.ch
More informationNeuro-Imaging in dementia: using MRI in routine work-up Prof. Philip Scheltens
Neuro-Imaging in dementia: Philip Scheltens Alzheimer Center VU University Medical Center Amsterdam The Netherlands 1 Outline of talk Current guidelines Imaging used to exclude disease Specific patterns
More informationNew life Collage of nursing Karachi
New life Collage of nursing Karachi Presenter: Zafar ali shah Faculty: Raja khatri Subject: Pathophysiology Topic :Alzheimer s Disease Post RN BScN semester 2 nd Objective Define Alzheimer s Describe pathophysiology
More informationThe Aging Brain The Aging Brain
The Aging Brain The Aging Brain R. Scott Turner, MD, PhD Director, Memory Disorders Program Professor, Department of Neurology Georgetown University Washington, DC memory.georgetown.edu rst36@georgetown.edu
More informationDementia, Cognitive Aging Services and Support
Dementia, Cognitive Aging Services and Support Ronald C. Petersen, Ph.D., M.D. Professor of Neurology Mayo Clinic College of Medicine Rochester, MN NASUAD Washington September 2, 2015 Disclosures Pfizer,
More informationWhat s New in Dementia?
What s New in Dementia? Howard Rosen Professor, Department of Neurology UCSF and Aging Center Disclosure Biogen pharmaceuticals Small grant for clinical trials planning Dementia is a growing source of
More informationPiramal Imaging to Present New Research in PET Imaging at Society of Nuclear Medicine and Molecular Imaging 2017 Annual Meeting
FOR IMMEDIATE RELEASE Media Contacts: Nicole Fletcher Piramal Imaging nicole.fletcher@piramal.com (857) 202-1122 Piramal Imaging to Present New Research in PET Imaging at Society of Nuclear Medicine and
More informationAlzheimer s Disease without Dementia
Alzheimer s Disease without Dementia Dr Emer MacSweeney CEO & Consultant Neuroradiologist Re:Cognition Health London Osteopathic Society 13 September 2016 Early diagnosis of Alzheimer s Disease How and
More information212 Index C-SB-13,
Index A Acetylcholinesterase inhibitor, treatment, 15 Age-associated memory impairment (AAMI), 5 Alzheimer s disease (AD), 40, 95 96 apolipoprotein E genotype and risk for, 58 cellular neurodegeneration
More informationWhite matter hyperintensities correlate with neuropsychiatric manifestations of Alzheimer s disease and frontotemporal lobar degeneration
White matter hyperintensities correlate with neuropsychiatric manifestations of Alzheimer s disease and frontotemporal lobar degeneration Annual Scientific Meeting Canadian Geriatric Society Philippe Desmarais,
More informationDementia mimicking Alzheimer s disease Owing to a tau mutation: CSF and PET findings
Dementia mimicking Alzheimer s disease Owing to a tau mutation: CSF and PET findings Chapter 4.2 N. Tolboom E.L.G.E. Koedam J.M. Schott M. Yaqub M.A. Blankenstein F. Barkhof Y.A.L. Pijnenburg A.A. Lammertsma
More informationAlzheimer disease and other types of
CMAJ Early release, published at www.cmaj.ca on April 11, 2016. Subject to revision. Practice CME Innovations Amyloid imaging for dementia in Canada Robert Laforce Jr MD PhD, Mohamed Réda Bensaïdane MSc
More informationDo not copy or distribute without permission. S. Weintraub, CNADC, NUFSM, 2009
Sandra Weintraub, Ph.D. Clinical Core Director, Cognitive Neurology and Alzheimer s Disease Center Northwestern University Feinberg School of Medicine Chicago, Illinois Dementia: a condition caused by
More information3/7/2017. Alzheimer s and Dementia Research: An Advanced Discussion. Alzheimer s and Dementia Research: An Advanced Discussion
Alzheimer s and Dementia Research: An Advanced Discussion Brad Boeve, MD Department of Neurology Mayo Clinic Alzheimer s and Dementia Research: An Advanced Discussion Theoretical Constructs in Aging/Dementia
More informationIl processo diagnostico dell Alzheimer dalla clinica al neuroimaging Giovanni B. Frisoni M.D.
Il processo diagnostico dell Alzheimer dalla clinica al neuroimaging Giovanni B. Frisoni M.D. Professor of Clinical Neurosciences, University of Geneva Médecin Responsable, Memory Clinic, Hôpitaux Universitaires
More informationMild Cognitive Impairment or Mild Neurocognitive Disorder: Implications for Clinical Practice. Hypothesized Key Players in the Pathogenesis of AD
AD is a Neurodegenerative Disease as Seen in the PET Scan and is Characterized by Amyloid Plaques and Neurofibrillary Tangles Mild Cognitive Impairment or Mild Neurocognitive Disorder: Implications for
More informationLANGUAGE AND PATHOLOGY IN FRONTOTEMPORAL DEGENERATION
LANGUAGE AND PATHOLOGY IN FRONTOTEMPORAL DEGENERATION Murray Grossman University of Pennsylvania Support from NIH (AG17586, AG15116, NS44266, NS35867, AG32953, AG38490), IARPA, ALS Association, and the
More informationSecondary prevention of Alzheimer s dementia: neuroimaging contributions
ten Kate et al. Alzheimer's Research & Therapy (2018) 10:112 https://doi.org/10.1186/s13195-018-0438-z RESEARCH Open Access Secondary prevention of Alzheimer s dementia: neuroimaging contributions Mara
More informationBiomarkers for Alzheimer s disease
Biomarkers for Alzheimer s Disease Henrik Zetterberg, MD, PhD Professor of Neurochemistry The Sahlgrenska Academy, University of Gothenburg 1 Alzheimer s disease 2 Neuropathological criteria for Alzheimer
More informationErin Cullnan Research Assistant, University of Illinois at Chicago
Dr. Moises Gaviria Distinguished Professor of Psychiatry, University of Illinois at Chicago Director of Consultation Liaison Service, Advocate Christ Medical Center Director of the Older Adult Program,
More informationUpdate on functional brain imaging in Movement Disorders
Update on functional brain imaging in Movement Disorders Mario Masellis, MSc, MD, FRCPC, PhD Assistant Professor & Clinician-Scientist Sunnybrook Health Sciences Centre University of Toronto 53 rd CNSF
More informationMP Amyloid Imaging With Positron Emission Tomography for Alzheimer Disease
Medical Policy MP 6.01.55 BCBSA Ref. Policy: 6.01.55 Last Review: 09/19/2018 Effective Date: 09/19/2018 Section: Radiology Related Policies 2.04.14 Biochemical Markers of Alzheimer Disease 6.01.54 Dopamine
More informationRoger E. Kelley, M.D. Professor and Chairman Department of Neurology Tulane University School of Medicine New Orleans, Louisiana
Roger E. Kelley, M.D. Professor and Chairman Department of Neurology Tulane University School of Medicine New Orleans, Louisiana FINANCIAL DISCLOSURE No potential conflict of interest to disclose. OBJECTIVES
More informationNACC Minimum Data Set (MDS) Public Data Element Dictionary
Department of Epidemiology, School of Public Health and Community Medicine, University of Washington 4311 11 th Avenue NE #300 Seattle, WA 98105 phone: (206) 543-8637; fax: (206) 616-5927 e-mail: naccmail@u.washington.edu
More informationImproving diagnosis of Alzheimer s disease and lewy body dementia. Brain TLC October 2018
Improving diagnosis of Alzheimer s disease and lewy body dementia Brain TLC October 2018 Plan for this discussion: Introduction to AD and LBD Why do we need to improve diagnosis? What progress has been
More informationWhat if it s not Alzheimer s? Update on Lewy body dementia and frontotemporal dementia
What if it s not Alzheimer s? Update on Lewy body dementia and frontotemporal dementia Dementia: broad term for any acquired brain condition impairing mental function such that ADLs are impaired. Includes:
More informationFlorbetaben for PET Imaging of Beta-Amyloid Plaques in the Brain
Neurol Ther (2014) 3:79 88 DOI 10.1007/s40120-014-0022-9 REVIEW Florbetaben for PET Imaging of Beta-Amyloid Plaques in the Brain Danielle Richards Marwan N. Sabbagh To view enhanced content go to www.neurologytherapy-open.com
More informationFrontotemporal dementia:
Frontotemporal dementia: Where we ve been What s on the horizon Howard Rosen, M.D. UCSF Department of Neurology Memory and Aging Center www.memory.ucsf.edu None Disclosures Overview FTD, What is it? Origins
More informationFrontotemporal Dementia: Towards better diagnosis. Frontotemporal Dementia. John Hodges, NeuRA & University of New South Wales, Sydney.
I.1 I.2 II.1 II.2 II.3 II.4 II.5 II.6 III.1 III.2 III.3 III.4 III.5 III.6 III.7 III.8 III.9 III.10 III.11 III.12 IV.1 IV.2 IV.3 IV.4 IV.5 Frontotemporal Dementia: Towards better diagnosis Frontotemporal
More informationSandra Weintraub, PhD Clinical Core Leader and Professor
Sandra Weintraub, PhD Clinical Core Leader and Professor Northwestern Cognitive Neurology and Alzheimer s Disease Center (CNADC) Chicago, Illinois www.brain.northwestern.edu Why is it so difficult to diagnose
More informationNCRAD. Single Gene Implicated in FTD/ALS UCSF Memory and Aging Center, San Francisco, California
The National Cell Repository for Alzheimer s Disease (NCRAD) is a data and specimen collection source for families with Alzheimer disease (AD) or serious memory loss. Families having two or more living
More informationWHAT IS DEMENTIA? An acquired syndrome of decline in memory and other cognitive functions sufficient to affect daily life in an alert patient
DEMENTIA WHAT IS DEMENTIA? An acquired syndrome of decline in memory and other cognitive functions sufficient to affect daily life in an alert patient Progressive and disabling Not an inherent aspect of
More informationUSE OF LABORATORY AND IMAGING INVESTIGATIONS IN DEMENTIA
USE OF LABORATORY AND IMAGING INVESTIGATIONS IN DEMENTIA c CLINICAL See end of article for authors affiliations Correspondence to: W M van der Flier, Department of Neurology and Alzheimer Center, Vrije
More informationFDG-PET e parkinsonismi
Parkinsonismi FDG-PET e parkinsonismi Valentina Berti Dipartimento di Scienze Biomediche, Sperimentali e Cliniche Sez. Medicina Nucleare Università degli Studi di Firenze History 140 PubMed: FDG AND parkinsonism
More informationMolecular Imaging and the Brain
Molecular imaging technologies are playing an important role in neuroimaging, a branch of medical imaging, by providing a window into the living brain. Where CT and conventional MR imaging provide important
More informationRecommendations for the Diagnosis and Treatment of Dementia 2012
Recommendations for the Diagnosis and Treatment of Dementia 2012 Based on the Canadian Consensus Conference on the Diagnosis and Treatment of Dementia (4 th CCCDTD) 2012 Gauthier S, Patterson C, Chertkow
More informationPathogenesis of Degenerative Diseases and Dementias. D r. Ali Eltayb ( U. of Omdurman. I ). M. Path (U. of Alexandria)
Pathogenesis of Degenerative Diseases and Dementias D r. Ali Eltayb ( U. of Omdurman. I ). M. Path (U. of Alexandria) Dementias Defined: as the development of memory impairment and other cognitive deficits
More informationDifferentiating Dementia Diagnoses
Differentiating Dementia Diagnoses Waitemata PHO 21 October 2014 Dr Michal Boyd, RN, NP, ND Nurse Practitioner Older Adults School of Nursing & Freemasons Dept. of Geriatric Medicine The University of
More informationUnited Council for Neurologic Subspecialties Geriatric Neurology Written Examination Content Outline
United Council for Neurologic Subspecialties Geriatric Neurology Written Examination Content Outline REV 3/24/09 The UCNS Geriatric Neurology examination was established to determine the level of competence
More informationDementia. Amber Eker, MD. Assistant Professor Near East University Department of Neurology
Dementia Amber Eker, MD Assistant Professor Near East University Department of Neurology Dementia An acquired syndrome consisting of a decline in memory and other cognitive functions Impairment in social
More informationPET ligands and metabolic brain imaging Prof. Karl Herholz
PET ligands Karl Herholz, University of Manchester PET images in this lecture, unless indicated otherwise, are from Max-Planck-Institute for Neurological Research, Cologne, Germany 1 Positron-Emission-Tomography
More informationMemory Matters: Learning Objectives: Synapses, Age, and Health. Neuronal Synapses DISCLOSURE DECLARATION. Cognition and Normal Aging
Standard Deviations from Mean Memory Matters: Preventing and Treating Late-Life, Cognitive Decline Daniel L. Murman, MD, MS Director, Behavioral and Geriatric Neurology Program Professor & Vice Chair,
More information